SERUM CONCENTRATIONS OF SOME ANGIOGENEIC FACTORS IN MULTIPLE MYELOMA: VEGF, bFGF IN MMP-9

  • Mojca Modic Klinični oddelek za hematologijo Klinični center Zaloška 7 1525 Ljubljana
  • Jana Kralj Klinični oddelek za hematologijo Klinični center Zaloška 7 1525 Ljubljana
  • Lara Čibej Klinični oddelek za hematologijo Klinični center Zaloška 7 1525 Ljubljana
  • Uroš Mlakar Klinični oddelek za hematologijo Klinični center Zaloška 7 1525 Ljubljana
Keywords: vascular endothelial growth factor, basic fibroblast growth factor, matrix metalloproteinase-9, multiple myeloma

Abstract

Background. Angiogenesis is a crucial process in progression of multiple myeloma. Vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF) are multifunctional cytokines that stimulate angiogenesis and myeloma growth. Matrix metalloproteinase 9 (MMP-9) plays a critical role in osteolytic bone destruction, angiogenesis and invasive growth of myeloma cells. We evaluated serum concentrations of these factors in patients with multiple myeloma.

Methods. Levels of active and pro-matrix metalloproteinase 9 (total MMP-9), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) were determined with a commercial quantitative enzyme immunoassay Quantikine  (R&D Systems, USA). All of these factors were measured in the serum obtained from pheripheral blood of 36 patients affected by multiple myeloma.This series included 12 patients with disease in plateau phase and without treatment, 14 patients on Thalidomide therapy and 10 patients at the beginning of chemotherapy because of active disease.

Results. VEGF showed a strong correlation with MMP-9 while VEGF and bFGF did not correlate with each other. Blood platelets correlated with VEGF and MMP-9.The concentration of MMP-9 and VEGF were the highest in group of patients with active disease where the chemotherapy started. The level of bFGF was the lowest in the group devoid of treatment (plateau phase of disease).

Conclusions. Production of the angiogenic factors such as VEGF, bFGF and MMP-9 are increased in multiple myeloma patients. The levels of these factors correlate with the activity of disease.

Downloads

Download data is not yet available.

References

Orpana A, Salven P. Angiogenic and lympangiogenic molecules in hematological malignancies. Leuk Lymphoma 2002; 43: 219–24.

Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 2002; 111: 43–51.

Kelly T, Borset M, Abe E, Gaddy-Kurten D, Sanderson RD. Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma 2000; 37: 273–81.

Vacca A, Di Loreto M, Ribatti et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM 1 and CD44.Am J Hematol 1995; 50: 9–14.

Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F & Dammacco F. Bone marrow angiogenesis and progressionn in multiple myeloma. British Journal of Haematology. 1994; 87: 503–8.

Rajkumar SV, Leong T, Roche PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research 2000; 6: 3111–6.

Vacca A, Ria R, Ribatti D, Semeraro F, Djonov V, Di Raimondo F, Dammacco F. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176–85.

Podar K, Tai YT, Davies FE et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 2001; 98: 428–35.

Di Raimondo F, Azzaro MP, Palumbo G et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85: 800–5.

Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer1998; 77: 956–64.

Casella I, Feccia T, Chelucci C et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood 2003; 101: 1316–23.

Barille S, Akhoundi C, Collette M et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 1997; 90: 1649–55.

Singhal S, Mehta J, Desikan R et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Eng J Med. 1999; 341: 1565–71.

Kakimoto T, Hattori Y, Okamoto S et al. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res 2002; 93: 1029–36.

Bertolini F, Mingrone W, Alietti A et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and surrogate angiogenesis markers. Annals of Oncology. 2001; 12: 987–90.

Neben K, Moehler T, Kraemer A, Benner A, Egerer G, Ho AD Goldschmidt. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol 2001; 115: 605–8.

Iwasaki T, Sano H. Predicting treatment responses and disease progression in myeloma using serum vascular endothelial growth factor and hepatocyte growth factor levels. Leuk Lymphoma 2003; 44: 1275–9.

Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E. Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002; 116: 796–802.

How to Cite
1.
Modic M, Kralj J, Čibej L, Mlakar U. SERUM CONCENTRATIONS OF SOME ANGIOGENEIC FACTORS IN MULTIPLE MYELOMA: VEGF, bFGF IN MMP-9. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];73. Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/2421
Section
Professional Article